ArticleDiscover oncology2025
Mendelian randomization reveals contrasting effects of immune signaling molecules on bone and articular cartilage malignancies.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe complex relationship between immune signaling molecules and cancer development remains incompletely understood. This study aimed to investigate potential causal relationships between specific immune factors and cancer risk via genetic instruments to overcome the limitations of traditional observational approaches.
methodsOur study employed Mendelian randomization (MR) analyses using genetic variants as instrumental variables for immune signaling molecules. Multiple analytical approaches, such as the inverse-variance weighted method, MR‒Egger regression, weighted median, and simple median, were applied to evaluate causal relationships. Forest plots, scatter plots, and funnel plots facilitated comprehensive assessment, whereas circular dendrogram visualization provided broader immune pathway context.
resultsOur study revealed significant bidirectional effects of immune signaling on cancer risk. Three immune factors demonstrated protective associations: C-C motif chemokine 4 (OR: 0.682, 95% CI: 0.509–0.915, p = 0.011), leukemia inhibitory factor receptor (OR: 0.588, 95% CI: 0.374–0.924, p = 0.021), and macrophage inflammatory protein (OR: 0.521, 95% CI: 0.345–0.786, p = 0.002). In contrast, C-X-C motif chemokine 6 exhibited risk-increasing effects (OR: 1.380, 95% CI: 1.014–1.878, p = 0.040). These findings were consistent across multiple analytical approaches and cancer types, including cervical cancer and bone/articular cartilage malignancies.
conclusionThis study provides genetic evidence supporting the causal impact of specific immune signaling molecules on cancer development, with different chemokines and inflammatory factors exerting opposing influences on disease susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.